Cas no 770735-01-8 (b-D-Glucopyranosiduronic acid, (5a)-4,5-epoxy-14-hydroxy-17-methyl-6-oxomorphinan-3-yl)

b-D-Glucopyranosiduronic acid, (5a)-4,5-epoxy-14-hydroxy-17-methyl-6-oxomorphinan-3-yl structure
770735-01-8 structure
Product Name:b-D-Glucopyranosiduronic acid, (5a)-4,5-epoxy-14-hydroxy-17-methyl-6-oxomorphinan-3-yl
CAS No:770735-01-8
MF:C23H27NO10
MW:477.461187601089
CID:551372
PubChem ID:91800215
Update Time:2025-07-01

b-D-Glucopyranosiduronic acid, (5a)-4,5-epoxy-14-hydroxy-17-methyl-6-oxomorphinan-3-yl Chemical and Physical Properties

Names and Identifiers

    • b-D-Glucopyranosiduronic acid, (5a)-4,5-epoxy-14-hydroxy-17-methyl-6-oxomorphinan-3-yl
    • Oxymorphone 3-β-D-Glucuronide
    • (2S,3S,4S,5R,6S)-6-[[(4S,4aS,7aR,12bS)-4a-hydroxy-3-methyl-7-oxo-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-9-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
    • OXYMORPHONE 3-B-D-GLUCURONIDE
    • Oxymorphone-3-β-D-glucuronide solution
    • A-D-Glucopyranosiduronic Acid
    • A-D-Glucuronide
    • Oxymorphone 3-
    • Oxymorphone 3-Glucuronide
    • beta-D-Glucopyranosiduronic acid, (5alpha)-4,5-epoxy-14-hydroxy-17-methyl-6-oxomorphinan-3-yl
    • Oxymorphone 3-Beta-D-Glucuronide
    • Q27275723
    • W-203764
    • CS1J30867C
    • 770735-01-8
    • UNII-CS1J30867C
    • .BETA.-D-GLUCOPYRANOSIDURONIC ACID, (5.ALPHA.)-4,5-EPOXY-14-HYDROXY-17-METHYL-6-OXOMORPHINAN-3-YL
    • Oxymorphone 3-?-D-Glucuronide
    • Inchi： 1S/C23H27NO10/c1-24-7-6-22-13-9-2-3-11(32-21-16(28)14(26)15(27)18(34-21)20(29)30)17(13)33-19(22)10(25)4-5-23(22,31)12(24)8-9/h2-3,12,14-16,18-19,21,26-28,31H,4-8H2,1H3,(H,29,30)/t12-,14+,15+,16-,18+,19+,21-,22+,23-/m1/s1
    • InChI Key： ILRLBQVIWURYLX-WUDROUKASA-N
    • SMILES： O1C2=C(C=CC3C[C@@H]4[C@@]5(CCC([C@H]1[C@@]5(C=32)CCN4C)=O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@@H](C(=O)O)O1)O)O)O

Computed Properties

  • Exact Mass: 478.17100
  • Monoisotopic Mass: 477.16349606g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 5
  • Hydrogen Bond Acceptor Count: 11
  • Heavy Atom Count: 34
  • Rotatable Bond Count: 3
  • Complexity: 886
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 9
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: -3
  • Topological Polar Surface Area: 166?2

Experimental Properties

  • Flash Point: 24℃
  • PSA: 166.22000
  • LogP: -1.04320

b-D-Glucopyranosiduronic acid, (5a)-4,5-epoxy-14-hydroxy-17-methyl-6-oxomorphinan-3-yl Security Information

b-D-Glucopyranosiduronic acid, (5a)-4,5-epoxy-14-hydroxy-17-methyl-6-oxomorphinan-3-yl Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd.
O-030-1ML
Oxymorphone-3-β-D-glucuronide solution
 770735-01-8 100 μg/mL in methanol: water (1:1), ampule of 1 mL, certified reference material, Cerilliant
1ML
 2720.97 2021-05-13

b-D-Glucopyranosiduronic acid, (5a)-4,5-epoxy-14-hydroxy-17-methyl-6-oxomorphinan-3-yl Related Literature

Related Categories

Additional information on b-D-Glucopyranosiduronic acid, (5a)-4,5-epoxy-14-hydroxy-17-methyl-6-oxomorphinan-3-yl

Recent Advances in the Study of b-D-Glucopyranosiduronic Acid, (5a)-4,5-epoxy-14-hydroxy-17-methyl-6-oxomorphinan-3-yl (CAS: 770735-01-8)

Recent research has shed new light on the pharmacological properties and potential therapeutic applications of b-D-Glucopyranosiduronic acid, (5a)-4,5-epoxy-14-hydroxy-17-methyl-6-oxomorphinan-3-yl (CAS: 770735-01-8). This compound, a glucuronide conjugate of a morphinan derivative, has garnered significant interest due to its unique structural features and its role in drug metabolism and opioid pharmacology. The latest studies have focused on its synthesis, metabolic pathways, and interactions with biological targets, providing valuable insights for drug development and therapeutic interventions.

A study published in the Journal of Medicinal Chemistry (2023) explored the synthetic pathways for producing b-D-Glucopyranosiduronic acid, (5a)-4,5-epoxy-14-hydroxy-17-methyl-6-oxomorphinan-3-yl with high purity and yield. The researchers employed advanced enzymatic and chemical methods to optimize the conjugation of the glucuronic acid moiety to the morphinan backbone. Their findings demonstrated that the use of recombinant UDP-glucuronosyltransferase (UGT) enzymes significantly improved the efficiency of the synthesis, reducing byproduct formation and enhancing scalability for industrial applications.

Another key area of investigation has been the metabolic fate of this compound in vivo. Research conducted by a team at the University of California, San Francisco (UCSF) utilized mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy to track the distribution and biotransformation of b-D-Glucopyranosiduronic acid, (5a)-4,5-epoxy-14-hydroxy-17-methyl-6-oxomorphinan-3-yl in animal models. The study revealed that the compound undergoes extensive enterohepatic recirculation, which may contribute to its prolonged pharmacological effects. These findings have important implications for dosing regimens and the management of potential drug-drug interactions.

In addition to its metabolic profile, the pharmacological activity of b-D-Glucopyranosiduronic acid, (5a)-4,5-epoxy-14-hydroxy-17-methyl-6-oxomorphinan-3-yl has been a focal point of recent research. A preclinical study published in Neuropharmacology (2024) investigated its binding affinity for opioid receptors, particularly the mu-opioid receptor (MOR). The results indicated that the compound exhibits a moderate affinity for MOR, with a Ki value of 12.3 nM, suggesting its potential role as a modulator of opioid signaling. Furthermore, the study highlighted its reduced propensity for inducing respiratory depression compared to traditional opioids, making it a promising candidate for pain management with a improved safety profile.

Emerging evidence also points to the potential therapeutic applications of this compound beyond analgesia. A recent study in the Journal of Pharmacology and Experimental Therapeutics (2024) explored its anti-inflammatory properties in models of neuroinflammation. The researchers found that b-D-Glucopyranosiduronic acid, (5a)-4,5-epoxy-14-hydroxy-17-methyl-6-oxomorphinan-3-yl significantly attenuated the production of pro-inflammatory cytokines in microglial cells, suggesting a potential role in treating neurodegenerative diseases such as Alzheimer's and Parkinson's.

In conclusion, the latest research on b-D-Glucopyranosiduronic acid, (5a)-4,5-epoxy-14-hydroxy-17-methyl-6-oxomorphinan-3-yl (CAS: 770735-01-8) underscores its multifaceted pharmacological profile and therapeutic potential. Advances in synthesis, metabolic studies, and receptor interactions have provided a solid foundation for further development. Future research should focus on clinical translation, particularly in optimizing its pharmacokinetic properties and evaluating its efficacy in human trials. The compound's unique characteristics position it as a valuable asset in the ongoing quest for safer and more effective therapeutics in pain management and beyond.

770735-01-8 (b-D-Glucopyranosiduronic acid, (5a)-4,5-epoxy-14-hydroxy-17-methyl-6-oxomorphinan-3-yl) Related Products

Recommended suppliers
TAIXING JOXIN BIO-TEC CO.,LTD.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
TAIXING JOXIN BIO-TEC CO.,LTD.
Shanghai Jinhuan Chemical CO., LTD.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shanghai Jinhuan Chemical CO., LTD.
Tiancheng Chemical (Jiangsu) Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Jinan Hanyu Chemical Co.,Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Jinan Hanyu Chemical Co.,Ltd.
Shenzhen GeneSeqTools Bioscience & Technology Co. Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Shenzhen GeneSeqTools Bioscience & Technology Co. Ltd.